28 June 2024 - Formycon and its licensing partner Klinge Biopharma announce that the US FDA today approved FYB203/Azhantive (aflibercept-mrbb), a biosimilar to Eylea.

FYB203/Azhantive obtained FDA approval for the treatment of patients with neovascular age-related (wet) macular degeneration and other serious retinal diseases such as diabetic macular oedema, diabetic retinopathy and macular oedema following retinal vein occlusion.

Read Formycon press release